StreetInsider.com News Articles

Form 10-Q OSR Health, Inc. For: Jun 30

Fri, 14 Aug 2026 15:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26929364.html

Form 10-Q OSR Health, Inc. For: Jun 30

Fri, 14 Aug 2026 15:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26929364.html

OSR Health faces Nasdaq deadline amid out-licensing talks

Tue, 11 Aug 2026 08:54:25 -0400

OSR Health, Inc. (NASDAQ: OSRH) disclosed that two of its subsidiaries have received inbound inquiries regarding potential out-licensing opportunities, as the company approaches a Nasdaq compliance deadline regarding its stock price.

In a letter to shareholders, CEO Peter Hwang stated that one subsidiary is at the preliminary term sheet negotiation phase, while a second is at an early stage. No parties or technologies were identified.

The company faces an August 18 deadline by which Nasdaq is expected to communicate its determination on OSRH's continued listing if the stock has not regained the minimum bid price requirement of $1.00 per share.

Hwang addressed shareholder

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

Tue, 11 Aug 2026 08:52:00 -0400

Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development

BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.

Dear Shareholders,

Today marks five business days before August 18, the practical deadline by which the Nasdaq is expected to communicate its determination regarding OSRH's continued listing if our stock price has not regained the minimum bid price requirement of $1.00 per share as of the market close.

As CEO of OSRH, I want to

OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development

Tue, 11 Aug 2026 08:52:00 -0400

Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development

BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from its Chief Executive Officer to shareholders.

Dear Shareholders,

As CEO of OSRH, I want to

Form 8-K OSR Health, Inc. For: Aug 07

Mon, 10 Aug 2026 11:09:00 -0400

si-local-file:///var/storage/secattach/20260810/26896082.html

Form 8-K OSR Health, Inc. For: Aug 07

Mon, 10 Aug 2026 11:09:00 -0400

si-local-file:///var/storage/secattach/20260810/26896082.html

Form 8-K OSR Health, Inc. For: Aug 07

Fri, 07 Aug 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260807/26890648.html

Form 8-K OSR Health, Inc. For: Aug 07

Fri, 07 Aug 2026 15:33:00 -0400

si-local-file:///var/storage/secattach/20260807/26890648.html

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Fri, 07 Aug 2026 15:00:00 -0400

BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning the Nasdaq Stock Market ("Nasdaq") and the Company's Shareholder Loyalty CVR Program.

The Company is clarifying that the statement in the prior release, "The communication affirms that our loyalty program is additive and gives shareholders clarity," should not be interpreted as indicating that Nasdaq has approved or endorsed the Shareholder Loyalty CVR Program.

Nasdaq's earlier communication was a preliminary, verbal indication limited

OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program

Fri, 07 Aug 2026 15:00:00 -0400

Nasdaq's earlier communication was a preliminary, verbal indication limited

Vaximm AG to submit glioblastoma vaccine trial data for publication

Mon, 03 Aug 2026 09:03:43 -0400

OSR Health, Inc. (NASDAQ: OSRH) announced that its subsidiary Vaximm AG has completed analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.

The company said it intends to submit the findings to a peer-reviewed scientific journal, with the manuscript expected to include safety and immunological data from the trials.

According to the press release, VXM01 as both monotherapy and in combination therapy showed no dose-limiting toxicities or high-grade treatment-related adverse events. The data also indicated successful activation of patients' immune systems against the target, dose-dependent

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Mon, 03 Aug 2026 09:02:00 -0400

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months

BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.

Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these results are indeed

Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform

Mon, 03 Aug 2026 09:02:00 -0400

Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months

Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these results are indeed

Form 8-K OSR Health, Inc. For: Jul 31

Fri, 31 Jul 2026 15:07:00 -0400

si-local-file:///var/storage/secattach/20260731/26850221.html

Form 8-K OSR Health, Inc. For: Jul 31

Fri, 31 Jul 2026 15:07:00 -0400

si-local-file:///var/storage/secattach/20260731/26850221.html

OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

Fri, 31 Jul 2026 12:00:00 -0400

BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication with the Company that the Company's Shareholder Loyalty Contingent Value Rights (CVR) program will not result in any mechanical adjustment to the price of OSR Health's common stock - either upon the distribution of the CVRs or upon the delivery of additional shares of common stock to enrolled holders under the program.

What this means for shareholders:

No mechanical price adjustment.

OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment

Fri, 31 Jul 2026 12:00:00 -0400

What this means for shareholders:

No mechanical price adjustment.

Form DEF 14A OSR Health, Inc. For: Aug 07

Thu, 16 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260716/26780164.html

Form DEF 14A OSR Health, Inc. For: Aug 07

Thu, 16 Jul 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20260716/26780164.html

Form PRE 14A OSR Health, Inc. For: Jul 06

Mon, 06 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260706/26736489.html

Form PRE 14A OSR Health, Inc. For: Jul 06

Mon, 06 Jul 2026 17:06:00 -0400

si-local-file:///var/storage/secattach/20260706/26736489.html

CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Thu, 02 Jul 2026 13:05:00 -0400

The tiered reward structure only has to be at or above the specified price level on the 3, 6, 9, or 12 month observation date. It was previously mentioned that the pricing needed to be sustained over that time period.

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (Nasdaq:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.

The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to

CORRECTION FROM SOURCE: Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Thu, 02 Jul 2026 13:05:00 -0400

The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to

Emerging Growth Research Issues Flash Report on OSR Health, Inc., Reaffirms Buy-Emerging Rating and $10.00 Price Target

Thu, 02 Jul 2026 09:00:00 -0400

NEW YORK CITY, NY / ACCESS Newswire / July 2, 2026 / Emerging Growth Research today issued a flash report on OSR Health, Inc. (NASDAQ:OSRH), formerly OSR Holdings, reaffirming its Buy-Emerging rating and 12-month price target of $10.00.

The flash report highlights OSRH's newly announced Shareholder Loyalty Program, a novel plan to reward long-term shareholders with Contingent Value Rights ("CVR") rather than pursuing a reverse stock split. The Company's Board has approved the plan, which remains subject to legal counsel's opinion, with a record date targeted for July 31, 2026.

Key Highlights From the